Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

NextCure, Inc. - Common Stock (NQ: NXTC )

0.8510 -0.0419 (-4.69%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 143,286
Open 0.8964
Bid (Size) 0.8280 (1)
Ask (Size) 0.9100 (25)
Prev. Close 0.8929
Today's Range 0.8300 - 0.8964
52wk Range 0.7710 - 2.570
Shares Outstanding 28,006,684
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
NextCure Announces Acceptance of IND Application for LNCB74
LNCB74 is a B7-H4-targeting antibody-drug conjugate being developed for multiple cancers in partnership with LigaChem Biosciences 
From NextCure
Via GlobeNewswire
NextCure to Participate in the 36th Annual Piper Sandler Healthcare Conference
From NextCure
Via GlobeNewswire

Performance

YTD
+3.53%
+3.53%
1 Month
-26.64%
-26.64%
3 Month
-38.33%
-38.33%
6 Month
-46.81%
-46.81%
1 Year
-26.00%
-26.00%

More News

Read More
Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis Imperfecta
From NextCure
Via GlobeNewswire
NXTC Stock Earnings: NextCure Beats EPS for Q4 2023
Via InvestorPlace
NextCure Provides Business Update and Reports Third Quarter 2024 Financial Results
From NextCure
Via GlobeNewswire
NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual Meeting
From NextCure
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting
From NextCure
Via GlobeNewswire
NextCure Presented Results of the Phase 1b Study of NC410 in Combination with Pembrolizumab at ESMO 2024
From NextCure
Via GlobeNewswire
NXTC Stock Earnings: NextCure Misses EPS for Q2 2024
Via InvestorPlace
NextCure Provides Business Update and Reports Second Quarter 2024 Financial Results
From NextCure
Via GlobeNewswire
NextCure to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
From NextCure
Via GlobeNewswire
NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024
From NextCure
Via GlobeNewswire
NXTC Stock Earnings: NextCure Misses EPS for Q1 2024
Via InvestorPlace
NextCure Provides Business Update and Reports First Quarter 2024 Financial Results
From NextCure
Via GlobeNewswire
NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024
From NextCure
Via GlobeNewswire
NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024
From NextCure
Via GlobeNewswire
NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board
From NextCure
Via GlobeNewswire
NextCure to Present at 23rd Annual Needham Virtual Healthcare Conference
From NextCure
Via GlobeNewswire
Wall Street’s Favorite Penny Stocks? 7 Names That Could Make You Filthy Rich
Via InvestorPlace
Topics Economy
Exposures Interest Rates
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
NextCure Provides Business Update and Reports Full Year 2023 Financial Results
From NextCure
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
NextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advances
From NextCure
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.